APO RESEARCH · REPORT
Neuromyelitis Optica Drug
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Product & engineering
Understand the product.
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
Selected research
Industry Growth & Trends
Global Neuromyelitis Optica Drug Industry Growth and Trends Forecast to 2032
Market perspective
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
According to APO Research, the global Neuromyelitis Optica Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Read the full market overview
Report Scope
This report provides a structured, data-driven view of the global Neuromyelitis Optica Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Neuromyelitis Optica Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neuromyelitis Optica Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neuromyelitis Optica Drug.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Neuromyelitis Optica Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Neuromyelitis Optica Drug Market by Company
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Neuromyelitis Optica Drug Segment by Type
Glucocorticoids
Immunotherapies
Others
Neuromyelitis Optica Drug Segment by Application
Acute Attack
Remission Prophylactic Treatment
Neuromyelitis Optica Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuromyelitis Optica Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuromyelitis Optica Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuromyelitis Optica Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Neuromyelitis Optica Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Glucocorticoids
- Immunotherapies
- Others
Applications
- Acute Attack
- Remission Prophylactic Treatment
Companies covered
- Pfizer
- Fresenius
- Teva
- Sandoz
- Intas
- Gyjtrs
- NANG KUANG
- Tianjin Kingyork
- Baxter
- CSL
- Grifols
- Octapharma
- CBOP
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Neuromyelitis Optica Drug Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Neuromyelitis Optica Drug Market Size by Region (2021-2032)
- 1.4.1 Global Neuromyelitis Optica Drug Market Size by Region (2021-2026)
- 1.4.2 Global Neuromyelitis Optica Drug Market Size by Region (2027-2032)
- 1.5 Key Regions Neuromyelitis Optica Drug Market Size (2021-2032)
- 1.5.1 North America Neuromyelitis Optica Drug Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Neuromyelitis Optica Drug Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Neuromyelitis Optica Drug Market Size Growth Rate (2021-2032)
- 1.5.4 South America Neuromyelitis Optica Drug Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Neuromyelitis Optica Drug Market Size Growth Rate (2021-2032)
2 Neuromyelitis Optica Drug Market by Type
- 2.1 Type Introduction
- 2.1.1 Glucocorticoids
- 2.1.2 Immunotherapies
- 2.1.3 Others
- 2.2 Global Neuromyelitis Optica Drug Market Size by Type
- 2.2.1 Global Neuromyelitis Optica Drug Market Size Overview by Type (2021-2032)
- 2.2.2 Global Neuromyelitis Optica Drug Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Neuromyelitis Optica Drug Market Size Forecasted by Type (2027-2032)
- 2.3 Global Neuromyelitis Optica Drug Market Size by Regions
- 2.3.1 North America Neuromyelitis Optica Drug Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Neuromyelitis Optica Drug Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Neuromyelitis Optica Drug Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Neuromyelitis Optica Drug Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Neuromyelitis Optica Drug Market Size Breakdown by Type (2021-2026)
3 Neuromyelitis Optica Drug Market by Application
- 3.1 Type Introduction
- 3.1.1 Acute Attack
- 3.1.2 Remission Prophylactic Treatment
- 3.2 Global Neuromyelitis Optica Drug Market Size by Application
- 3.2.1 Global Neuromyelitis Optica Drug Market Size Overview by Application (2021-2032)
- 3.2.2 Global Neuromyelitis Optica Drug Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Neuromyelitis Optica Drug Market Size Forecasted by Application (2027-2032)
- 3.3 Global Neuromyelitis Optica Drug Market Size by Regions
- 3.3.1 North America Neuromyelitis Optica Drug Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Neuromyelitis Optica Drug Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Neuromyelitis Optica Drug Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Neuromyelitis Optica Drug Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Neuromyelitis Optica Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Neuromyelitis Optica Drug Industry Trends
- 4.2 Neuromyelitis Optica Drug Industry Drivers
- 4.3 Neuromyelitis Optica Drug Industry Opportunities and Challenges
- 4.4 Neuromyelitis Optica Drug Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Neuromyelitis Optica Drug Revenue (2021-2026)
- 5.2 Global Neuromyelitis Optica Drug Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Neuromyelitis Optica Drug Key Company Headquarters & Area Served
- 5.4 Global Neuromyelitis Optica Drug Company, Product Type & Application
- 5.5 Global Neuromyelitis Optica Drug Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Neuromyelitis Optica Drug Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Neuromyelitis Optica Drug Players Market Share by Revenue in 2025
- 5.6.3 2025 Neuromyelitis Optica Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Pfizer
- 6.1.1 Pfizer Company Information
- 6.1.2 Pfizer Business Overview
- 6.1.3 Pfizer Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Pfizer Neuromyelitis Optica Drug Product Portfolio
- 6.1.5 Pfizer Recent Developments
- 6.2 Fresenius
- 6.2.1 Fresenius Company Information
- 6.2.2 Fresenius Business Overview
- 6.2.3 Fresenius Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Fresenius Neuromyelitis Optica Drug Product Portfolio
- 6.2.5 Fresenius Recent Developments
- 6.3 Teva
- 6.3.1 Teva Company Information
- 6.3.2 Teva Business Overview
- 6.3.3 Teva Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Teva Neuromyelitis Optica Drug Product Portfolio
- 6.3.5 Teva Recent Developments
- 6.4 Sandoz
- 6.4.1 Sandoz Company Information
- 6.4.2 Sandoz Business Overview
- 6.4.3 Sandoz Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Sandoz Neuromyelitis Optica Drug Product Portfolio
- 6.4.5 Sandoz Recent Developments
- 6.5 Intas
- 6.5.1 Intas Company Information
- 6.5.2 Intas Business Overview
- 6.5.3 Intas Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Intas Neuromyelitis Optica Drug Product Portfolio
- 6.5.5 Intas Recent Developments
- 6.6 Gyjtrs
- 6.6.1 Gyjtrs Company Information
- 6.6.2 Gyjtrs Business Overview
- 6.6.3 Gyjtrs Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Gyjtrs Neuromyelitis Optica Drug Product Portfolio
- 6.6.5 Gyjtrs Recent Developments
- 6.7 NANG KUANG
- 6.7.1 NANG KUANG Company Information
- 6.7.2 NANG KUANG Business Overview
- 6.7.3 NANG KUANG Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 NANG KUANG Neuromyelitis Optica Drug Product Portfolio
- 6.7.5 NANG KUANG Recent Developments
- 6.8 Tianjin Kingyork
- 6.8.1 Tianjin Kingyork Company Information
- 6.8.2 Tianjin Kingyork Business Overview
- 6.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Product Portfolio
- 6.8.5 Tianjin Kingyork Recent Developments
- 6.9 Baxter
- 6.9.1 Baxter Company Information
- 6.9.2 Baxter Business Overview
- 6.9.3 Baxter Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Baxter Neuromyelitis Optica Drug Product Portfolio
- 6.9.5 Baxter Recent Developments
- 6.10 CSL
- 6.10.1 CSL Company Information
- 6.10.2 CSL Business Overview
- 6.10.3 CSL Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 CSL Neuromyelitis Optica Drug Product Portfolio
- 6.10.5 CSL Recent Developments
- 6.11 Grifols
- 6.11.1 Grifols Company Information
- 6.11.2 Grifols Business Overview
- 6.11.3 Grifols Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Grifols Neuromyelitis Optica Drug Product Portfolio
- 6.11.5 Grifols Recent Developments
- 6.12 Octapharma
- 6.12.1 Octapharma Company Information
- 6.12.2 Octapharma Business Overview
- 6.12.3 Octapharma Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Octapharma Neuromyelitis Optica Drug Product Portfolio
- 6.12.5 Octapharma Recent Developments
- 6.13 CBOP
- 6.13.1 CBOP Company Information
- 6.13.2 CBOP Business Overview
- 6.13.3 CBOP Neuromyelitis Optica Drug Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 CBOP Neuromyelitis Optica Drug Product Portfolio
- 6.13.5 CBOP Recent Developments
7 North America
- 7.1 North America Neuromyelitis Optica Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Neuromyelitis Optica Drug Market Size by Country (2021-2026)
- 7.3 North America Neuromyelitis Optica Drug Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Neuromyelitis Optica Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Neuromyelitis Optica Drug Market Size by Country (2021-2026)
- 8.3 Europe Neuromyelitis Optica Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Neuromyelitis Optica Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Neuromyelitis Optica Drug Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Neuromyelitis Optica Drug Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Neuromyelitis Optica Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Neuromyelitis Optica Drug Market Size by Country (2021-2026)
- 10.3 South America Neuromyelitis Optica Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Neuromyelitis Optica Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Neuromyelitis Optica Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst